Actively Recruiting
Study of Elsunersen Treatment in Children With Early-Onset SCN2A Developmental and Epileptic Encephalopathy
Led by Praxis Precision Medicines · Updated on 2026-08-03
40
Participants Needed
10
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
This clinical trial evaluates the efficacy and safety of elsunersen in children with early-onset SCN2A Developmental and Epileptic Encephalopathy, a condition characterized by seizures beginning before 3 months of age. The study focuses on pediatric participants confirmed to have a gain of function SCN2A genetic variant, aiming to understand how elsunersen impacts seizure frequency and related symptoms. The trial is sponsored by Praxis Precision Medicines and is conducted at multiple centers. Participants receive intrathecal doses of elsunersen every 4 weeks for a total of 24 weeks. Two dosing levels, 1mg and 0.5mg, are being studied in an open-label design across three cohorts. All participants receive the study drug without a placebo comparison, and treatment effects on seizures and other clinical assessments are monitored throughout the treatment period. During the 24-week treatment, participants undergo regular evaluations to assess seizure frequency, clinical global impression of severity and improvement, and sleep quality among other outcomes. Safety and tolerability are also closely monitored. The trial includes baseline observation periods and follow-up assessments to track changes over time, providing a comprehensive view of elsunersens impact in this pediatric population.
CONDITIONS
Brief Title
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
Research Team
H
Head of Pharmacovigilance
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here